Group 1 - WuXi AppTec and Dongyao Pharmaceutical announced a voluntary conditional cash offer at HKD 4 per share, representing a 99% premium over Dongyao's closing price of HKD 2.01 on the last unaffected trading day [1] - The offer involves all issued shares of Dongyao and plans to cancel all unexercised stock options, with a maximum consideration of approximately HKD 2.79 billion [1] - WuXi AppTec intends to maintain Dongyao's listing status on the Hong Kong Stock Exchange post-transaction [1] Group 2 - The acquisition aims to expand WuXi AppTec's operational manufacturing capacity in China, aligning with its business development plans to enhance project portfolio and customer base in the ADC CDMO sector [3] - WuXi AppTec forecasts a revenue growth of over 45% and a gross profit increase of over 70% for the fiscal year 2025, with adjusted net profit expected to rise by over 45% [3] - Excluding currency fluctuations, the growth rates are anticipated to exceed 65% [3] Group 3 - Recent developments in China's innovative drug research include the announcement by Weili Zhibo regarding its PD-L1/4-1BB bispecific antibody receiving fast track designation from the FDA [3] - During the 2026 JPMorgan Healthcare Conference, Fuhong Hanlin announced a global exclusive licensing agreement with Youmai Bio for a monoclonal antibody targeting interleukin-1 receptor accessory protein [3] - BioNTech revealed plans to initiate six Phase III clinical trials in 2026, including a key clinical study for the B7H3 ADC new drug BNT324/DB-1311 developed in collaboration with Yingensheng Bio [3]
药明合联溢价99%收购东曜药业，2025财年盈利预增超45%